Tesaro was founded in 2010.[1] The company's first commercial product,Varubi, was approved by theFDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[5] On December 3, 2018,GSK announced it would acquire the company for $5.1 billion,[6] and the deal was completed on January 22, 2019.[7]
Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.[8]
TSR-042
TSR-022
Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
